Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2021 Feb 12

PMID 33572717

Citations 4

Authors

Katrine Melby

Mona Nygard

Mathias Forsberg Brobakken

Rolf W Grawe

Ismail Cuneyt Guzey

Solveig Klaebo Reitan

Einar Vedul-Kjelsas

Jorn Heggelund

Mariela Loreto Lara-Cabrera

Affiliations

Soon will be listed here.

Abstract

Patient Activation Measure-13 (PAM-13) is a valid and widely used questionnaire that assess an individual's knowledge, confidence, and skills for self-management of their chronic illness. Although there is some evidence regarding its reliability, the test-retest reliability has not been investigated among patients with substance use disorders (SUDs) or schizophrenia spectrum disorders. We investigated the internal consistency and test-retest reliability of PAM-13 in these populations. Test-retest reliability was analysed using data from 29 patients with SUDs and 28 with schizophrenia spectrum disorders. Cronbach's α and Intraclass Correlation Coefficient (ICC) scores were used to examine internal consistency and test-retest reliability, respectively. Of the 60 collected test-retest questionnaires, 57 were included in the analyses. No mean differences between time one (T1) and time two (T2) were observed in either patient group, except for item 12 in schizophrenia spectrum disorders patients ( < 0.05). Internal consistency for T1 and T2 was 0.75 and 0.84 in SUDs patients and 0.87 and 0.81 in schizophrenia spectrum disorders patients, respectively. The ICC was r = 0.86 in patients with SUDs and r = 0.93 in patients with schizophrenia spectrum disorders. To conclude, PAM-13 showed good internal consistency and test-retest reliability in SUDs and schizophrenia spectrum disorders patients.

Citing Articles

Application of the PAPERS Grading Criteria Within a Rapid Evidence Review to Determine the Psychometric and Pragmatic Properties of Patient Empowerment Tools.

Woolley K, Jones N, Rahim A, Withers K, Letchford R J Patient Exp. 2024; 11:23743735241272191.

PMID: 39176305 PMC: 11339745. DOI: 10.1177/23743735241272191.

A Systematic Review of the Reliability and Validity of the Patient Activation Measure Tool.

Ng Q, Liau M, Tan Y, Tang A, Ong C, Thumboo J Healthcare (Basel). 2024; 12(11).

PMID: 38891154 PMC: 11171848. DOI: 10.3390/healthcare12111079.

Testing the validation and reliability of the Caregiver-Patient Activation Measure (CG-PAM).

Carleton-Eagleton K, Walker I, Gibson D, Freene N, Semple S PEC Innov. 2023; 1:100098.

PMID: 37213753 PMC: 10194270. DOI: 10.1016/j.pecinn.2022.100098.

Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above.

Zrubka Z, Vekas P, Nemeth P, Dobos A, Hajdu O, Kovacs L Eur J Health Econ. 2022; 23(8):1341-1355.

PMID: 35102464 PMC: 9550701. DOI: 10.1007/s10198-022-01434-0.

References

Bomba F, Markwart H, Muhlan H, Menrath I, Ernst G, Thyen U . Adaptation and validation of the German Patient Activation Measure for adolescents with chronic conditions in transitional care: PAM 13 for Adolescents. Res Nurs Health. 2017; 41(1):78-87. DOI: 10.1002/nur.21831. View

Lara-Cabrera M, Salvesen O, Nesset M, De Las Cuevas C, Iversen V, Grawe R . The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres. Patient Educ Couns. 2015; 99(5):760-8. DOI: 10.1016/j.pec.2015.11.028. View

Heggelund J, Hoff J, Helgerud J, Nilsberg G, Morken G . Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia. BMC Psychiatry. 2011; 11:188. PMC: 3280309. DOI: 10.1186/1471-244X-11-188. View

Young J, Heffernan E, Borschmann R, Ogloff J, Spittal M, Kouyoumdjian F . Dual diagnosis of mental illness and substance use disorder and injury in adults recently released from prison: a prospective cohort study. Lancet Public Health. 2018; 3(5):e237-e248. DOI: 10.1016/S2468-2667(18)30052-5. View

Salyers M, Matthias M, Spann C, Lydick J, Rollins A, Frankel R . The role of patient activation in psychiatric visits. Psychiatr Serv. 2009; 60(11):1535-9. PMC: 2777630. DOI: 10.1176/appi.ps.60.11.1535. View

Nygard M, Brobakken M, Roel R, Taylor J, Reitan S, Guzey I . Patients with schizophrenia have impaired muscle force-generating capacity and functional performance. Scand J Med Sci Sports. 2019; 29(12):1968-1979. DOI: 10.1111/sms.13526. View

Kosar C, Buyukkaya Besen D . Adaptation of a patient activation measure (PAM) into Turkish: reliability and validity test. Afr Health Sci. 2019; 19(1):1811-1820. PMC: 6531939. DOI: 10.4314/ahs.v19i1.58. View

Davoli M, Bargagli A, Perucci C, Schifano P, Belleudi V, Hickman M . Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007; 102(12):1954-9. DOI: 10.1111/j.1360-0443.2007.02025.x. View

Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H . Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013; 8(1):e55176. PMC: 3555866. DOI: 10.1371/journal.pone.0055176. View

10.

Gunatilake S, Ananth J, Parameswaran S, Brown S, Silva W . Rehabilitation of schizophrenic patients. Curr Pharm Des. 2004; 10(18):2277-88. DOI: 10.2174/1381612043384141. View

11.

Bahrom N, Ramli A, Isa M, Baharudin N, Badlishah-Sham S, Mohamed-Yassin M . Validity and reliability of the Patient Activation Measure® (PAM®)-13 Malay version among patients with Metabolic Syndrome in primary care. Malays Fam Physician. 2020; 15(3):22-34. PMC: 7735884. View

12.

Prinsen C, Mokkink L, Bouter L, Alonso J, Patrick D, de Vet H . COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018; 27(5):1147-1157. PMC: 5891568. DOI: 10.1007/s11136-018-1798-3. View

13.

Keszei A, Novak M, Streiner D . Introduction to health measurement scales. J Psychosom Res. 2010; 68(4):319-23. DOI: 10.1016/j.jpsychores.2010.01.006. View

14.

Hibbard J, Greene J . What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013; 32(2):207-14. DOI: 10.1377/hlthaff.2012.1061. View

15.

Kinney R, Lemon S, Person S, Pagoto S, Saczynski J . The association between patient activation and medication adherence, hospitalization, and emergency room utilization in patients with chronic illnesses: a systematic review. Patient Educ Couns. 2015; 98(5):545-52. DOI: 10.1016/j.pec.2015.02.005. View

16.

Kim S, Kim E, Ryu E . Illness Perceptions, Self-Care Management, and Clinical Outcomes According to Age-Group in Korean Hemodialysis Patients. Int J Environ Res Public Health. 2019; 16(22). PMC: 6888085. DOI: 10.3390/ijerph16224459. View

17.

Cunha C, Cunha D, Manzato R, Nepomuceno E, da Silva D, Aparecida Spadoti Dantas R . Validation of the Brazilian Version of the Patient Activation Measure 13. J Nurs Meas. 2019; 27(1):97-113. DOI: 10.1891/1061-3749.27.1.97. View

18.

Hibbard J, Stockard J, Mahoney E, Tusler M . Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004; 39(4 Pt 1):1005-26. PMC: 1361049. DOI: 10.1111/j.1475-6773.2004.00269.x. View

19.

Brobakken M, Nygard M, Taylor J, Guzey I, Morken G, Reitan S . A comprehensive cardiovascular disease risk profile in patients with schizophrenia. Scand J Med Sci Sports. 2019; 29(4):575-585. DOI: 10.1111/sms.13371. View

20.

Druss B, Singh M, von Esenwein S, Glick G, Tapscott S, Tucker S . Peer-Led Self-Management of General Medical Conditions for Patients With Serious Mental Illnesses: A Randomized Trial. Psychiatr Serv. 2018; 69(5):529-535. PMC: 5930018. DOI: 10.1176/appi.ps.201700352. View